ArticleBiomedical chromatography : BMC2026
A Principle-Guided Multistep Workflow for Screening Potential Quality Marker Candidates of Sanqi Shangyao Tablet Based on UHPLC-Q-Orbitrap MS, In Silico Screening, and In Vitro Validation.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Quality marker (Q-marker) screening is crucial for the quality control of traditional Chinese medicine (TCM) formulas but remains challenging. In this study, a principle-guided multistep strategy was established for the rational identification of potential Q-marker candidates in Sanqi Shangyao tablet (SST). Ultrahigh-performance liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry was employed for comprehensive chemical profiling, followed by traceability assessment and relative specificity estimation. A total of 124 compounds were characterized, among which 66 were confirmed using authentic standards. After successive filtering based on traceability, relative specificity, and drug-like properties, 25 candidate compounds were retained and associated with 163 osteoarthritis-related targets. Enrichment analysis identified the TNF signaling pathway as a key regulatory axis, and network topology analysis prioritized prunetin for further investigation. In IL-1β-stimulated chondrocytes, prunetin showed no apparent cytotoxicity at concentrations up to 50 μM, significantly reduced nitric oxide production, suppressed pro-inflammatory mediators, and attenuated extracellular matrix degradation. Molecular dynamics simulations provided supportive structural evidence for favorable interactions between prunetin and representative targets, including MAPK14, PTGS2, and AKT1. Based on integrated chemical, biological, and TCM theory considerations, six compounds were proposed as potential Q-marker candidates. This study provides a practical workflow for preliminary Q-marker candidate prioritization in complex herbal formulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.